Kevin Young, Gilead’s newly-appointed chief operating officer, agreed that the pace of new patient treatments may slow in coming years, but added that “quantifying that pace is incredibly hard.” ...

Kevin Young’s first regular season at BYU is in the books. Young’s Cougars are heading into the Big 12 tournament on an eight game winning streak, with a 85-74 victory over rival Utah Saturday ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

There are a lot of new and returning shows to check out this spring, including new shows from Shonda Rhimes and Amy ...

Wanda Sykes has a hilarious reason why she wanted to play Kevin Hart’s mother in his new animated series, “Lil Kev.” “I get to yell at Kevin all time,” she deadpanned to CNN.

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

Hopefully a new standard of care for the aggressive disease, according to partners Gilead Sciences and Merck & Co. Gilead's Trop-2 targeting antibody-drug conjugate Trodelvy (sacituzumab govitecan ...

Martin Scorsese is collaborating with Apple for his upcoming feature, an adaptation of the Gilead novel with Leonardo DiCaprio attached to lead.

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine. However, Ben Hargreaves finds that the company’s ...

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a takeover by Gilead Sciences in a $405 million deal.

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...